Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While conventional systemic agents and TNF-α inhibitors historically dominated early-line therapy, recent years have seen a gradual shift toward earlier use of non-TNF biologics, particularly IL-17 inhibitors (e.g., Cosentyx, Taltz, Bimzelx) and IL-23 inhibitors (e.g., Tremfya, Skyrizi), driven by their superior efficacy and more favorable long-term safety profiles. The market has further expanded with the increased uptake of oral targeted therapies, including PDE4 inhibitor Otezla and, more recently, the oral TYK2 inhibitor Sotyktu, offering non-injectable options for psoriasis patients. Despite the availability of multiple treatments for psoriasis, a substantial unmet need remains. Novel agents are needed that can differentiate on the attributes of efficacy, safety, delivery, and ability to treat a broad patient population.
QUESTIONS ANSWERED
- How do dermatologists rate the performances of Bimzelx, Sotyktu, and their competitors on key treatment drivers and goals for moderate to severe psoriasis?
- Which clinical and nonclinical attributes are key influencers of dermatologists’ prescribing decisions, and which have limited impact? What are areas of hidden opportunity?
- What are the key unmet needs and leading opportunities in the treatment of moderate to severe psoriasis?
- What trade-offs across key clinical / nonclinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new drug for moderate to severe psoriasis?
PRODUCT DESCRIPTION
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European dermatologists
Key drugs: Humira, Stelara, Taltz, Bimzelx, Skyrizi, Otezla, Sotyktu
Key analyses
- Importance of clinical and nonclinical product attributes to physicians
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Remaining drug development opportunities
